Data Factory
Reading the graph
Reading the graph
Private Equity
The Woodlands, TX
As a healthcare growth equity firm, we empower companies in the US and Europe to drive positive change in healthcare while delivering high returns.
Data as of (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built and rebuilt at most every 15 minutes.
| Fund | Vintage | Lifecycle | ADV type | Form D sold | GAV | LPs |
|---|---|---|---|---|---|---|
| Emerald Holdco US, LP | 2024 | Unknown | Private Equity Fund | n/a | $235M | 0 |
| Zephyr Fund 3 Holdco US, L.P. | 2024 | Unknown | Private Equity Fund | n/a | $179M | 0 |
| Midas Co-Investment Fund, L.P. | 2023 | Early deployment | Private Equity Fund | n/a | $9.9M | 0 |
| Atlas Co-Investment Fund 2, L.P. | 2022 | Early deployment | Private Equity Fund | n/a | $53.0M | 0 |
| EW Healthcare Partners Fund 3, L.P. | 2022 | Early deployment | Private Equity Fund | n/a | $324M | 0 |
| EW Healthcare Partners Fund 3-A, L.P. | 2022 | Early deployment | Private Equity Fund | n/a | $420M | 0 |
| EW Healthcare Partners Acquisition Fund, L.P. | 2021 | Active deployment | Private Equity Fund | n/a | $81.6M | 0 |
| Falcon Co-Investment Fund 2, L.P. | 2021 | Active deployment | Private Equity Fund | n/a | $41.7M | 0 |
| Mercury Co-Investment Fund 2, L.P. | 2020 | Wound down | Private Equity Fund | n/a | $6.6M | 0 |
| EW Healthcare Partners Fund 2-A, L.P. | 2020 | Mature | Private Equity Fund | n/a | $407M | 0 |
| Titan Co-Investment Fund 2, L.P. | 2020 | Active deployment | Private Equity Fund | n/a | $49.6M | 0 |
| SC Essex Topaz Co-Invest II, LP | 2019 | Harvest | Private Equity Fund | n/a | $94,240 | 0 |
| Biotoscana Secondary Investment S.C.S. | 2019 | Wound down | Private Equity Fund | n/a | $45.4M | 0 |
| Essex Topaz Co-Investment III LP | 2019 | Harvest | Private Equity Fund | n/a | $109,682 | 0 |
| Essex Topaz Co-Investment IV, LP | 2019 | Harvest | Private Equity Fund | n/a | $96,572 | 0 |
| EW Healthcare Partners Fund 2, L.P. | 2019 | Mature | Private Equity Fund | n/a | $263M | 0 |
| Essex Topaz Co-Investment, LP | 2019 | Wound down | Private Equity Fund | n/a | $227M | 0 |
| Essex Woodlands Fund Ix-A, LP | 2016 | Mature | Private Equity Fund | n/a | $13.2M | 0 |
| Essex Woodlands Fund Ix, LP | 2015 | Mature | Private Equity Fund | n/a | $337M | 0 |
| Essex Woodlands Health Ventures Fund Viii-A, LP | n/a | Wound down | Private Equity Fund | n/a | $18.6M | 0 |
| Essex Woodlands Health Ventures Fund Viii, LP | n/a | Wound down | Private Equity Fund | n/a | $258M | 1 |
| Essex Woodlands Special Situation Fund, LP | n/a | Wound down | Private Equity Fund | n/a | $44.1M | 0 |
| Essex Woodlands Health Ventures Fund VII, LP | n/a | Harvest | Venture Capital Fund | n/a | $8.1M | 1 |
| Essex Woodlands Health Ventures Fund Viii-B, LP | n/a | Wound down | Private Equity Fund | n/a | $8.1M | 0 |
| Company | State | Role | Control | Invested | Exited | Status |
|---|---|---|---|---|---|---|
| EUSA Pharma | n/a | unknown | unknown | n/a | n/a | active |
| Bioventus | n/a | unknown | unknown | n/a | n/a | active |
| Ascend | n/a | unknown | unknown | n/a | n/a | active |
| Cardiva Medical | n/a | unknown | unknown | n/a | n/a | active |
| MediciNova, Inc | n/a | unknown | unknown | n/a | n/a | active |
| Suneva Medical | n/a | unknown | unknown | n/a | n/a | active |
| BioTissue | n/a | unknown | unknown | n/a | n/a | active |
| Acura Pharmaceuticals, Inc | n/a | unknown | unknown | n/a | n/a | active |
| Cota | n/a | unknown | unknown | n/a | n/a | active |
| Boiron | n/a | unknown | unknown | n/a | n/a | active |
| Pharmaceuticals | n/a | unknown | unknown | n/a | n/a | unknown |
| Medtech | n/a | unknown | unknown | n/a | n/a | unknown |
| Tech-Enabled Services | n/a | unknown | unknown | n/a | n/a | unknown |
| Encore Dermatology | n/a | unknown | unknown | n/a | n/a | active |
| EyePoint Pharmaceuticals, Inc | n/a | unknown | unknown | n/a | n/a | active |
| VitalConnect | n/a | unknown | unknown | n/a | n/a | active |
| Breg | n/a | unknown | unknown | n/a | n/a | active |
| Axogen | n/a | unknown | unknown | n/a | n/a | active |
| Serene, LLC | n/a | unknown | unknown | n/a | n/a | active |
| Metabolon, Inc | Nc | unknown | unknown | n/a | n/a | active |
| Cognate Bioservices | n/a | unknown | unknown | n/a | n/a | active |
| TELA Bio | n/a | unknown | unknown | n/a | n/a | active |
| Prolacta Bioscience | n/a | unknown | unknown | n/a | n/a | active |
| Laboratoires Majorelle | n/a | unknown | unknown | n/a | n/a | active |
| Germfree Laboratories | n/a | unknown | unknown | n/a | n/a | active |
| Grundium Oy | n/a | unknown | unknown | n/a | n/a | active |
| Sonendo, Inc. | CA | unknown | unknown | n/a | n/a | active |
| Enercon Technologies | n/a | unknown | unknown | n/a | n/a | active |
| MiMedx Group | n/a | unknown | unknown | n/a | n/a | active |
| Venus Concept | n/a | unknown | unknown | n/a | n/a | active |
| Limited partner | Fund | Commitment | Committed | Vintage |
|---|---|---|---|---|
| Washington State Investment Board | n/a | $25.0M | n/a | 2000 |
| Washington State Investment Board | n/a | $25.0M | n/a | 2004 |
| Oregon Public Employees Retirement Fund | n/a | $25.0M | n/a | 2004 |
| Oregon Public Employees Retirement Fund | Essex Woodlands Health Ventures Fund VII, LP | $50.0M | n/a | 2006 |
| Oregon Public Employees Retirement Fund | Essex Woodlands Health Ventures Fund Viii, LP | $100M | n/a | 2008 |
| Massachusetts Pension Reserves Investment Management Board | n/a | n/a | n/a | n/a |
| Los Angeles City Employees' Retirement System | n/a | $4.0M | n/a | 1998 |
| Los Angeles City Employees' Retirement System | n/a | $10.0M | n/a | 2000 |
| Los Angeles City Employees' Retirement System | n/a | $15.0M | n/a | 2004 |
Also named here, with no published line of their own (reach them through the firm): Immanuel Nmn Thangaraj (Managing Director), Gregory Lee Hill (Cco, Cfo), Richard Lee Kolodziejcyk (Cfo - Legacy Funds), Jeff Sugita Himawan (Managing Director), Martin Paul Sutter (President, Director, Secretary, Managing Director).
Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan